title: Rifampicin and Parkinson's disease.
abstract: Rifampicin is a macrocyclic antibiotic used extensively for the treatment of Mycobacterium tuberculosis and other mycobacterial infections. Recently, it was discovered that rifampicin exhibits neuroprotective effects. It has been shown to protect PC12 cells against MPP(+)-induced apoptosis and inhibit the expression of α-synuclein multimers. In in vitro studies, rifampicin pretreatment protects PC12 cells against rotenone-induced cell death. Qualitative and quantitative analyses uncover that rifampicin significantly suppresses rotenone-induced apoptosis by ameliorating mitochondrial oxidative stress. It reduces microglial inflammation and improves neuron survival. Our results indicate that rifampicin is cytoprotective under a variety of experimental conditions, and suggest that it may be useful in PD therapeutics. It is the aim of this paper to review the experimental neuroprotection data reported using rifampicin with a focus on the molecular and cellular mechanisms of cytoprotective effect in in vitro models of PD.
authors: Department of Neurology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, People's Republic of China.
authors: Wei
authors: W
authors: Bi
authors: Lihong
authors: L
authors: Zhu
authors: Xiuna
authors: X
authors: Jing
authors: Yanran
authors: Y
authors: Liang
authors: Enxiang
authors: E
authors: Tao
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018384:Oxidative Stress / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D012293:Rifampin